Stock Events

Stock Events

DBV Technologies 

€0
0
+€0+0% Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

4MayExpected
Next
-0.02
0.31
0.64
0.98
Expected EPS
-0.022908214212
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow DBV.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap80.54B
Regeneron Pharmaceuticals, involved in developing treatments for allergies and inflammatory diseases, competing in the broader allergy treatment market.
Sanofi
SNY
Mkt Cap116.63B
Sanofi, a large pharmaceutical company with a focus on immunology and allergy treatments, including collaborations on therapies that could compete with DBV's offerings.
Novavax
NVAX
Mkt Cap1.25B
Novavax, works on vaccines that could potentially address allergies, indirectly competing by targeting the underlying causes of allergic reactions.
Moderna
MRNA
Mkt Cap19.51B
Moderna, known for mRNA technology, which could be applied to develop vaccines or treatments for allergies, potentially competing with DBV's approach.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.67B
BioMarin Pharmaceutical, focuses on rare diseases but has interests in developing treatments that could overlap with allergy and immunotherapy markets.
Adma Biologics
ADMA
Mkt Cap2.19B
ADMA Biologics, specializes in immune globulin products which could be used in treating allergies, offering an alternative to DBV's therapies.
Vertex Pharmaceuticals
VRTX
Mkt Cap111.43B
Vertex Pharmaceuticals, while primarily focused on cystic fibrosis, its research into other areas of medicine could lead to competitive treatments in the allergy space.
GSK
GSK
Mkt Cap113.29B
GlaxoSmithKline, a large pharmaceutical company with a diverse portfolio, including respiratory and allergy treatments, potentially competing across several areas of DBV's interest.

About

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. The company's product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. Its earlier stage research programs include vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.
Show more...
CEO
Mr. Daniel Tassé
Employees
117
Country
Germany
ISIN
FR0010417345

Listings

MU
DE
DBV.MU
F
DE
DBV1.F
STU
DE
DBV1.STU
STU
DE
DBV.STU

0 Comments

Share your thoughts

FAQ

What is DBV Technologies stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange DBV Technologies stocks are traded under the ticker DBV.MU.
When is the next DBV Technologies earnings date?▼
DBV Technologies is going to release the next earnings report on May 04, 2026.
How many employees does DBV Technologies have?▼
As of April 12, 2026, the company has 117 employees.
In which sector is DBV Technologies located?▼
DBV Technologies operates in the Other sector.
When did DBV Technologies complete a stock split?▼
DBV Technologies has not had any recent stock splits.
Where is DBV Technologies headquartered?▼
DBV Technologies is headquartered in Châtillon, Germany.